knowledge -WSS

knowledge

author：hotspot 2025-09-05 08:10:07 - browse：64673

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Steward Health Care files for bankruptcy

focus

WSS

CMS should re

Elevance, private equity launch primary care company

Making AI in medicine accessible to smaller, and rural hospitals

After gene therapy, two congenitally deaf children hear for the first time

Researchers on aging grapple with how to calculate biological age

STAT letters to the editor on burnt

entertainment

knowledge

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

What PEPFAR has meant on the ground in Ukraine

Peter Hotez and the public health issue of online harassment

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to improve immunocompromised access to mAb treatments

Malaria cases in Florida and Texas: Here’s what you need to know

Patients' immediate access to test results puts radiologists in a bind

How to save PrEP access — and even expand it

Software glitch causes Tandem insulin pump to shutdown, FDA warns

hotspot

Study: Adult vaccinations pay for themselves in societal benefits

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

H5N1 communication has been strictly for the birds

Sanofi strikes deal with Novavax, boosting the vaccine maker

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Why sickle cell disease is getting the first CRISPR treatment

knowledge

focus

explore

hotspot